Source Type,Source,Subject,Object,Predicate
PMID,12036898.0,"Leukemia, Lymphocytic, Acute",Child,PROCESS_OF
PMID,12036898.0,Child,CDKN2A gene | CDKN2A,LOCATION_OF
PMID,27502091.0,"Leukemia, Lymphocytic, Acute, L1",Adolescent,PROCESS_OF
PMID,27502091.0,"Leukemia, Lymphocytic, Acute, L1",Child,PROCESS_OF
PMID,28983018.0,"Leukemia, Lymphocytic, Acute",Adolescent,PROCESS_OF
PMID,28983018.0,"Leukemia, Lymphocytic, Acute",Child,PROCESS_OF
PMID,28983018.0,Drug Kinetics,Young adult,PROCESS_OF
PMID,28983018.0,Drug Kinetics,Adolescent,PROCESS_OF
PMID,28983018.0,Drug Kinetics,Child,PROCESS_OF
PMID,28983018.0,"Leukemia, Lymphocytic, Acute",Young adult,PROCESS_OF
PMID,28809761.0,Hematologic Neoplasms,Child,PROCESS_OF
PMID,28809761.0,"Leukemia, B-Cell, Acute",Hematologic Neoplasms,ISA
PMID,28809761.0,"Leukemia, B-Cell, Acute",Child,PROCESS_OF
PMID,28983018.0,Pharmacotherapy,Child,TREATS
PMID,28983018.0,"Leukemia, Lymphocytic, Acute",Child,PROCESS_OF
PMID,28983018.0,Pharmacotherapy,"Leukemia, Lymphocytic, Acute",TREATS
PMID,29417201.0,Therapeutic procedure,RFP2 gene,USES
PMID,29417201.0,Therapeutic procedure,Pharmacotherapy,compared_with
PMID,29417201.0,Induction,"Leukemia, Lymphocytic, Acute",TREATS
PMID,29417201.0,leukemia,Patients,PROCESS_OF
PMID,29417201.0,"Leukemia, Lymphocytic, Acute",Patients,PROCESS_OF
PMID,29417201.0,"Receptors, Antigen",T-Lymphocyte,AFFECTS
PMID,29417201.0,Transplanted organ and tissue status,Patients,PROCESS_OF
PMID,29417201.0,Therapeutic procedure,"Leukemia, Lymphocytic, Acute",TREATS
NCT,NCT03020030,Malignant Neoplasms,Child,PROCESS_OF
NCT,NCT03020030,"Leukemia, Lymphocytic, Acute",Malignant Neoplasms,ISA
NCT,NCT03020030,"Leukemia, Lymphocytic, Acute",Child,PROCESS_OF
NCT,NCT03020030,"Leukemia, Lymphocytic, Acute",Child,PROCESS_OF(SPEC)
NCT,NCT03020030,Cells,Malignant Neoplasms,LOCATION_OF
NCT,NCT03020030,Disease,Child,PROCESS_OF
NCT,NCT03020030,Disease,Adolescent,PROCESS_OF
NCT,NCT03020030,Therapeutic procedure,"Leukemia, Lymphocytic, Acute",TREATS
NCT,NCT03020030,Pharmaceutical Preparations,Child,NEG_TREATS
NCT,NCT03020030,Pharmaceutical Preparations,Adolescent,NEG_TREATS
NCT,NCT03020030,Pharmaceutical Preparations,"Leukemia, Lymphocytic, Acute",NEG_TREATS(INFER)
NCT,NCT03020030,"Leukemia, Lymphocytic, Acute",Child,PROCESS_OF
NCT,NCT03020030,"Leukemia, Lymphocytic, Acute",Adolescent,PROCESS_OF
NCT,NCT03020030,Therapeutic procedure,Child,ADMINISTERED_TO
NCT,NCT03020030,Therapeutic procedure,Adolescent,ADMINISTERED_TO
NCT,NCT03020030,Blood,pegaspargase,LOCATION_OF
NCT,NCT03020030,Therapeutic procedure,"Leukemia, Lymphocytic, Acute",TREATS
NCT,NCT03020030,"Leukemia, Lymphocytic, Acute",Child,PROCESS_OF
NCT,NCT03020030,Therapeutic procedure,Child,TREATS
NCT,NCT03020030,Therapeutic procedure,"Leukemia, Lymphocytic, Acute",TREATS(INFER)
NCT,NCT03020030,Blood,leukemia,LOCATION_OF
NCT,NCT03020030,Cells,Genetic Materials,LOCATION_OF
NCT,NCT03020030,Chromosomes,leukemia,LOCATION_OF
NCT,NCT03020030,Leukemic Cell,leukemia,LOCATION_OF
NCT,NCT03020030,Marrow,leukemia,LOCATION_OF
NCT,NCT03020030,leukemia,Child,PROCESS_OF
NCT,NCT03020030,Genes,Leukemic Cell,PART_OF
NCT,NCT03020030,Therapeutic procedure,Participant,TREATS
NCT,NCT03020030,Therapeutic procedure,Participant,TREATS
NCT,NCT03020030,Pharmaceutical Preparations,"Leukemia, Lymphocytic, Acute",TREATS
NCT,NCT03020030,pegaspargase,Pharmaceutical Preparations,ISA
NCT,NCT03020030,pegaspargase,"Leukemia, Lymphocytic, Acute",TREATS(SPEC)
NCT,NCT03020030,Therapeutic procedure,Adverse effects,CAUSES
NCT,NCT03020030,Blood,pegaspargase,LOCATION_OF
NCT,NCT03020030,Pharmaceutical Preparations,pegaspargase,compared_with
NCT,NCT03020030,Pharmaceutical Preparations,pegaspargase,higher_than
NCT,NCT03020030,"Leukemia, Lymphocytic, Acute",Child,PROCESS_OF
NCT,NCT03020030,"Leukemia, Lymphocytic, Acute",Adolescent,PROCESS_OF
NCT,NCT00042341,"Leukemia, Lymphocytic, Acute",Adult,PROCESS_OF
NCT,NCT00042341,clofarabine,Therapeutic procedure,ISA
NCT,NCT00042341,clofarabine,Injection procedure,ISA
NCT,NCT00042341,clofarabine,"Leukemia, Lymphocytic, Acute",TREATS
NCT,NCT00042341,Medication Management,Therapeutic procedure,METHOD_OF
NCT,NCT00042341,clofarabine,Patients,TREATS
NCT,NCT00042341,clofarabine,Patients,TREATS
NCT,NCT02228096,"Leukemia, B-Cell, Acute",Patients,PROCESS_OF
NCT,NCT02228096,"Therapies, Investigational",Patients,TREATS
NCT,NCT02228096,"Therapies, Investigational","Leukemia, B-Cell, Acute",TREATS(INFER)
NCT,NCT02819804,Malignant Neoplasms,"Leukemia, Lymphocytic, Acute",COEXISTS_WITH
NCT,NCT02819804,Therapeutic procedure,Disease,TREATS
NCT,NCT02819804,Medication Management,Therapeutic procedure,METHOD_OF
NCT,NCT02819804,ABL1 gene,Cells,AUGMENTS
NCT,NCT02819804,Pharmaceutical Preparations,Pharmaceutical Preparations,compared_with
NCT,NCT02819804,Pharmaceutical Preparations,Pharmaceutical Preparations,higher_than
NCT,NCT02819804,Philadelphia chromosome positive,Patients,PROCESS_OF
NCT,NCT02819804,Toxic effect,Patients,PROCESS_OF
NCT,NCT02819804,Bone Marrow,PDCD1 gene,LOCATION_OF
NCT,NCT02819804,peripheral blood,PDCD1 gene,LOCATION_OF
NCT,NCT02819804,Peripheral,T-Lymphocyte,LOCATION_OF
NCT,NCT02819804,Therapeutic procedure,Patients,TREATS
NCT,NCT02819804,Therapeutic procedure,Patients,ADMINISTERED_TO
NCT,NCT02819804,Hemopoietic stem cell transplant,Patients,ADMINISTERED_TO
NCT,NCT01471782,"Leukemia, Lymphocytic, Acute",Patients,PROCESS_OF
NCT,NCT01471782,Malignant Neoplasms,Blood,PART_OF
NCT,NCT01471782,Malignant Neoplasms,Bone Marrow,PART_OF
NCT,NCT01471782,"Leukemia, Lymphocytic, Acute",Malignant Neoplasms,ISA
NCT,NCT01471782,"Leukemia, Lymphocytic, Acute",Blood,PART_OF(SPEC)
NCT,NCT01471782,"Leukemia, Lymphocytic, Acute",Bone Marrow,PART_OF(SPEC)
NCT,NCT01471782,"Leukemia, Lymphocytic, Acute, L1","Leukemia, Lymphocytic, Acute",ISA
NCT,NCT01471782,"Leukemia, Lymphocytic, Acute",Patients,PROCESS_OF
NCT,NCT01471782,Drug Kinetics,Patients,PROCESS_OF
NCT,NCT01471782,Part,Cells,LOCATION_OF
NCT,NCT01471782,T-Cell Activation,Patients,PROCESS_OF
NCT,NCT01471782,Drug Kinetics,cohort,PROCESS_OF
NCT,NCT01471782,Pharmacotherapy,Participant,ADMINISTERED_TO
NCT,NCT01471782,"Leukemia, Lymphocytic, Acute",Patients,PROCESS_OF
Section,Prognostic Factors,Lymphatic Diseases,Mediastinal mass,COEXISTS_WITH
Section,Prognostic Factors,Serum,Immunoglobulins,LOCATION_OF
Section,Prognostic Factors,White Blood Cell Count procedure,"Leukemia, B-Cell, Acute",DIAGNOSES
Section,Prognostic Factors,"Leukemia, B-Cell, Acute",Patients,PROCESS_OF
Section,Prognostic Factors,Chemotherapy-Oncologic Procedure,Girls,TREATS
Section,Prognostic Factors,Hyperploidy,Boys,OCCURS_IN
Section,Prognostic Factors,Mutation,Patients,AFFECTS
Section,Prognostic Factors,hLL2 agent,Monoclonal Antibodies,ISA
Section,Prognostic Factors,Child,Single Nucleotide Polymorphism,LOCATION_OF
Section,Prognostic Factors,Pharmacotherapy,Therapeutic procedure,compared_with
Section,Prognostic Factors,Patients,TAF1 gene,LOCATION_OF
Section,Prognostic Factors,Therapeutic procedure,Racial group,TREATS
Section,Prognostic Factors,"Receptors, Antigen",FASTK Gene,STIMULATES
Section,Prognostic Factors,Pharmacotherapy,Patients,TREATS
Section,Prognostic Factors,Hemopoietic stem cell transplant,Patients,TREATS
Section,Prognostic Factors,Induction,Patients,TREATS
Section,Prognostic Factors,Cells,Immunoglobulins,LOCATION_OF
Section,Prognostic Factors,Cells,"Genes, T-Cell Receptor",LOCATION_OF
Section,Prognostic Factors,Flow Cytometry,"Neoplasm, Residual",DIAGNOSES
Section,Prognostic Factors,Obesity,Patients,PROCESS_OF
Section,Prognostic Factors,host,Toxic effect,LOCATION_OF
Section,Prognostic Factors,Intervention regimes,Therapeutic procedure,COEXISTS_WITH
